Video
Virtual genetics board to discuss high-risk localized prostate cancer, BRCA1-related management
Author(s):
“We will also cover options for germline testing—different ways that tests can be ordered, panel options that are available commercially,” says Veda N. Giri, MD.
Video Player is loading.
In this video, Veda N. Giri, MD, offers a preview of the ENGAGEMENT Study Virtual Genetics Board’s upcoming case discussion, which you can sign up for by going to www.prostategenetics.com/engagement. The event will take place December 14 at 12 pm ET. Giri is a Professor in Medical Oncology and Cancer Biology at Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania.
Related Videos
Naeem Bhojani, MD, discusses WATER III data on Aquablation vs enucleation for BPH
Matthew Galsky, MD, reacts to NIAGARA results, durvalumab approval for MIBC
Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
Timothy Lyon, MD, on recent change to outpatient complications metric in urology rankings
Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
Jason Hafron, MD, considers the future for AI in urology
Sima Porten, MD, discusses the need to educate on the firefighter-bladder cancer link
Eugene Cone, MD, outlines potential impact of Expanded Access Program for rBCG
Investigators evaluate tamsulosin use in pediatric patients
Ruchika Talwar, MD, on how urologists can get involved in advocacy
Related Content
